Normal View Dyslexic View
Author response: Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial
Related articles
Comment on: Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial
Wei-Zhen Tang, MD1, Zhi-jian Zhou, MD, Tai-Hang Liu, PhD1
1. Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China
Correspondence to: Wei-Zhen Tang (2021220107@stu.cqmu.edu.cn) and Tai-Hang Liu (liuth@cqmu.edu.cn)
Chongqing Medical University
No.1 Yixueyuan Rd, Box 197
Chongqing 400016
China
DOI: https://doi.org/10.58974/bjss/azbc059
Dear Editor
After analysis of the research findings by Schiavone et al.1, we acknowledge the efficacy of Lugol’s solution in reducing FT3 and FT4 levels. However, the study also indicates that the preoperative use of Lugol’s solution did not significantly reduce intraoperative bleeding, the duration of surgery, or postoperative complications in patients with Graves’ disease undergoing total thyroidectomy. The study concludes that preoperative Lugol’s solution should not be considered mandatory for these patients. Nevertheless, we believe that there are several issues within the study that could impact on the accuracy of the results.
Comment on: Parathyroid vascular anatomy using intraoperative mapping angiography: the PARATLAS study
Rajni K Sah, Sabaretnam Mayilvaganan
Correspondence to: Sabaretnam Mayilvaganan (drretnam@gmail.com)
Additional Professor
Department of Endocrine Surgery